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Energizing miRNA research: a review of the role of miRNAs in lipid
metabolism, with a prediction that miR-103/107 regulates human
metabolic pathways
Bernard R. Wilfred1, Wang-Xia Wang1, and Peter T. Nelson1,*
1 Sanders-Brown Center on Aging and Department of Pathology, Division of Neuropathology, University of
Kentucky, Lexington, KY 40536 USA
Abstract
MicroRNAs (miRNAs) are powerful regulators of gene expression. Although first discovered in
worm larvae, miRNAs play fundamental biological roles—including in humans—well beyond
development. MiRNAs participate in the regulation of metabolism (including lipid metabolism) for
all animal species studied. A review of the fascinating and fast-growing literature on miRNA
regulation of metabolism can be parsed into three main categories: 1. Adipocyte biochemistry and
cell fate determination; 2. Regulation of metabolic biochemistry in invertebrates; and 3. Regulation
of metabolic biochemistry in mammals. Most research into the ‘function’ of a given miRNA in
metabolic pathways has concentrated on a given miRNA acting upon a particular ‘target’ mRNA.
Whereas in some biological contexts the effects of a given miRNA:mRNA pair may predominate,
this might not be the case generally. In order to provide an example of how a single miRNA could
regulate multiple ‘target’ mRNAs or even entire human metabolic pathways, we include a discussion
of metabolic pathways that are predicted to be regulated by the miRNA paralogs, miR-103 and
miR-107. These miRNAs, which exist in vertebrate genomes within introns of the pantothenate
kinase (PANK) genes, are predicted by bioinformatics to affect multiple mRNA targets in pathways
that involve cellular Acetyl-CoA and lipid levels. Significantly, PANK enzymes also affect these
pathways, so the miRNA and ‘host’ gene may act synergistically. These predictions require
experimental verification. In conclusion, a review of the literature on miRNA regulation of
metabolism leads us believe that the future will provide researchers with many additional energizing
revelations.
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Introduction
MicroRNAs (miRNAs) are small regulatory RNAs that play fundamental biological roles in
all known plant and animal species. Translational regulation by miRNAs has emerged as a
complex biological paradigm, involving interdependent genes and pathways. Many of the
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genes regulated by miRNAs are also involved in metabolism, including in pathways involved
in lipid biochemistry. The regulation of metabolism by miRNAs is only partly understood.
However, a review of the literature provides early indications that miRNA research will be
energizing researchers in the field for years to come.
A grasp of basic miRNA biochemistry is required to consider how miRNAs could regulate
metabolic pathways. Fundamental miRNA biology has been well reviewed previously[1–4].
In the human genome, miRNA genes can exist singly or can be co-transcribed in a ‘poly-
cistronic’ arrangement[5,6]. Many miRNAs are paralogous (i.e., similar to one another and
possibly derived from gene duplication). The transcription and downstream processing of
miRNAs is complex and beyond the scope of this review[7–14]. Briefly, miRNAs are
transcribed from intergenic regions, from introns, or more infrequently from within exons of
known protein-coding genes[15]. Intronic miRNAs may be co-transcribed with the ‘parent’
mRNAs (usually by RNA polymerase II), or may be transcribed independently[15–18]. Large
precursor RNAs called “pri-miRNAs” are sequentially cleaved in the nucleus, exported to the
cytoplasm, and then processed further to produce ‘mature’ (~22 nucleotides in length) single-
stranded miRNAs that are bound to Argonaute proteins[19,20]. MiRNAs are thought to
function by recognizing ‘target’ mRNAs through partial base-pair complementarity, and this
recognition leads to a decrease in the rate at which a polypeptide is correctly formed from that
mRNA template. As shown in Fig. 1, the specificity of the interaction is conferred by the
miRNAs, but the translational inhibition is coordinated by miRNA-associated Argonaute
proteins. The mechanism(s) by which Argonaute proteins function have been at least partly
described [21–24]. It should be noted that targeted mRNAs may be preferentially degraded,
so that translational regulation is not the only mechanism by which miRNAs work[25,26].
Complementing cellular and molecular biological studies, bioinformatics have also been very
important in driving the field of miRNA research. Among other things, bioinformatics
techniques are used to predict which miRNAs can regulate which target mRNAs[27–34].
Theses studies involve the cross-correlation between miRNA sequences and potential
hybridizing sequences in known and annotated genomes. Individual miRNAs can each
recognize many different mRNAs, up to a thousand or more[29,35]. Thus it is considered that
40–90% of human mRNAs are regulated by known miRNAs (and many more miRNAs are
probably unknown)[35,36]. The prediction algorithms for miRNA interactions with mRNAs
vary, however, these criteria are considered important: 1. metazoan miRNA recognition sites
are thought to reside within the 3′UTR (untranslated region) of target mRNAs ([37,38];
however see [39]); 2. the 5′ half of the miRNA appears most important in binding to mRNAs
[31,40]; and, 3. mRNA 3′UTR sequences demonstrate relative evolutionary degeneration (i.e.,
increased numbers of mutations), so potential 3′UTR target mRNA sequences that are
evolutionarily conserved and also recognized by miRNAs are thought to most likely represent
genuine miRNA recognition motifs whose function confers a fitness advantage (see [30,32,
34]).
Research on the role of miRNAs in metabolism
Boinformatics and bench research have combined to establish that miRNAs participate in
fundamental functions in animal and plant biology. Accordingly, miRNAs participate in
metabolism--making energy available to an organism. Thus far research in this field is in its
infancy, and much remains to be learned (for excellent prior reviews, see [41–44]). Some
research findings will be summarized below with an emphasis on the metabolism of lipids.
These studies, which are summarized in Table 1, fall under three categories: 1. Adipocyte
biochemistry and cell fate determination; 2. Regulation of metabolic biochemistry in
invertebrates; and 3. Regulation of metabolic biochemistry in mammals.
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MiRNA regulation in adipocytes in culture
MiRNAs were discovered in the context of the heterochronic developmental pathway in C.
elegans [45,46]. Hence, it is well known that miRNAs can play a role in development and cell
fate determination. Adipocytes are cells which provide retrievable fat and energy depots in
animal species. Several labs have now found evidence that miRNAs are involved in the
developmental maturation of adipocytes from precursor cells called pre-adipocytes. These
experiments have mostly involved cultured pre-adipocytes, which can be stimulated to
differentiate into a phenotype resembling mature fat-storing adipocytes. Kajimito et al [47]
found in 3T3-LI pre-adipocytes in culture, 80 different miRNAs are expressed and 21
individual miRNAs are differentially expressed in the course of pre-adipocyte differentiation
(most of the changes taking place in the late stages of differentiation). However, inhibiting the
function of individual miRNAs (including miR-143) did not alter the course of the pre-
adipocyte differentiation, nor did these perturbations alter the mRNA levels of marker genes
PPAR-gamma, A-FABP, or adiponectin. In these cells, both miR-103 and miR-143 tended
toward higher expression in more differentiated cells. Esau et al [48] demonstrated in cultured
human pre-adipocytes that inhibiting miR-143 also inhibited adipocyte differentiation in those
cells, and the authors hypothesized that this effect may occur through the targeting by miR-143
of the mRNA for the protein ERK5. Hence in cells whose physiological function is involved
in lipid metabolism, miRNAs are abundant, and may play a role in determining the terminal
cell phenotype.
In addition to playing a role in adipocyte cell fate determination, bioinformatics have been
applied to predict a major role for miRNAs in the steady-state function of pre-adipocytes and
adipocytes. Hackl et al [36] performed high-throughput analyses of the 3′ UTR from ESTs
expressed in 3T3-LI pre-adipocyte cells. Data derived from the study of hundreds of ESTs
showed that >70% of differentially expressed genes are predicted to be regulated by miRNAs
that were known at that time. Many of the mRNAs predicted to be regulated by miRNAs
encoded transcription factors, so the effects of miRNA regulation may be amplified. These
data are highly suggestive that miRNAs play important, dynamic roles, in regulating the
function of fat cells.
Regulation of metabolic biochemistry in invertebrates
Although cells in culture offer advantages for experimental manipulation, invertebrate models
can be used to study whole-animal genetics. Metabolic regulation occurs at many different
interdependent levels and miRNA regulation may be involved at all levels of regulation.
Intriguing results have been obtained in Drosophila with regard to individual miRNAs with
organism-level regulation of metabolic pathways. These pathways intersect with other aspects
of those animals’ biochemical milieu. Teleman et al [49] demonstrated that flies that lack a
particular miRNA (miR-278) have metabolic defects. MiR-278 (a miRNA expressed most
abundantly in Drosophila adipose tissue) mutants have increased insulin production and lower
levels of adipose, but also have elevated circulating glucose levels due to increased glycogen
mobilization, and decreased insulin sensitivity. These changes are hypothesized to involve a
pathway that incorporates the polypeptide product of the gene expanded. Xu et al [50] showed
the importance of another Drosophila miRNA--miR-14--to energy metabolism at the whole-
animal level. MiR-14 evidently plays a role in fat metabolism, as well as in cell death, and also
in the animals’ response to environmental stress. Animals with miR-14 deletions have
increased circulating fats, and increased peripheral lipid droplets. The authors speculate on the
role for miR-14 in ‘lipoapoptosis’. There are no known exact human orthologs to Drosophila
miR-14 and miR-278. However, some human miRNAs show sequence homology: human
miR-511 and miR-620 resemble Drosophila miR-14, and human miR-658 and miR-583
resemble Drosophila miR-278 (for example, the sequence for hsa-miR-658 shares 15 of 22nts
in sense orientation with dme-miR-278). Whether or not these miRNAs play a role in human
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metabolism remains to be seen. Dovetailing on the work in fruit flies is research involving
metabolism and miRNAs in worms[51]. C. elegans was the species in which miRNAs were
first discovered and these animals continue to be a source of insights into miRNA biology.
Boehm and Slack [52] showed that in worms, as in fruit flies, lifespan and metabolic pathways
interact through pathways that include miRNAs and insulin processing.
Regulation of metabolic biochemistry in mammals
Recent work in mammalian metabolism has complemented the earlier, and on-going,
invertebrate studies. This research introduces new paradigms in both mammalian metabolism
and miRNA biochemistry. Poy et al [53] studied miRNAs in mouse pancreas, and reported
that miRNAs can be involved in the dynamic biochemistry of the cell. This important finding
shows that miRNAs don’t merely regulate discreet developmental stages (i.e., cell fate
determination). In these studies they found that mouse insulin secretion is regulated by the
pancreatic miRNA mmu-miR-375, an evolutionarily-conserved islet-specific miRNA.
Myotrophin is evidently the target of miR-375, and this miRNA:target interaction regulates
the secretion of insulin. The regulation of exocytosis machinery is probably a widespread
phenomenon because many miRNAs are predicted to target exocytosis-related proteins[41].
Plaisance et al [54] showed that miR-9 causes a reduction in exocytosis in pancreas (insulin-
secreting beta cells) that is elicited by stimuli including glutamate. MiR-9 is hypothesized to
act in this context ultimately by affecting the concentration of granulophilin/Slp4. This effect,
mimicked by various pharmacological and biochemical means, demonstrates that a miRNA
can be active in maintaining metabolism-related function in endocrine cells. It should be noted
that miR-9 is also predicted to regulate almost 1000 other target mRNAs[29], and miR-9 is
very concentrated in the human brain[16,55], where it may be related to malignant
transformation of glioma cells [56].
One of the few published examples of miRNAs regulating a metabolic pathway per se involves
miR-29b, which Mersey et al [57] demonstrate may be involved in the metabolism of amino
acids in HEK 293 cells. This activity evidently occurs through regulation of the mRNA for the
dihydrolipoamide branched chain acyltransferase subcomponent of the branched chain alpha-
ketoacid dehydrogenase (BCKD) complex. This finding is very significant because it places
miRNAs for the first time in a mammalian species as a co-regulator of a complex metabolic
pathway. In sum, mammal-oriented research on miRNA regulation of metabolism has given
us new insights into the roles that miRNAs can play. However, every new datum thus far has
only indicated that we probably have much more yet to learn.
The focal point of many lines of research is therapy for human diseases, and the miRNA
pathways are excellent candidates for pharmacological manipulation[58–61]. Fascinating
recent work [62,63]demonstrates that the regulation of metabolic pathways in humans is of
direct, practical interest as a candidate for therapeutic measures. Esau et al [63] focused on the
miRNA pathway itself as a potential target for pharmacological intervention in an animal
model. This study involved the injection of a miR-122 antagonist (an antisense oligonucleotide
with 2′-O-methoxyethyl phosphororothiate) into mice that resulted in decreased plasma
cholesterol levels and hepatic fatty acid and cholesterol synthesis. Fatty acid metabolism was
altered with decreased amounts of fatty acid metabolism-related mRNA levels for genes such
as ACACA, ACACB, ACLY, FASN, LIPC, SCD1, and others. The authors proposed that this
reagent would be a good therapeutic candidate for metabolic disease.
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Bioinformatics predict a role for miR-103/miR-107 paralogs in lipid and
energy metabolism
With some notable exceptions described above, most research about the ‘function’ of a given
miRNA in metabolism has concentrated on the impact of a particular miRNA:mRNA
interaction. Whereas the effects of a given miRNA:mRNA pair may predominate in some
biological contexts, this may not generally be true. After all, many miRNAs are predicted by
bioinformatics to help regulate well over 1,000 different target mRNAs[29,35]. In order to
provide an example of how a given miRNA could alter entire human metabolic pathways, this
review incorporates a discussion of a metabolic pathway in which multiple different mRNAs
may be regulated by a few, highly-similar miRNA genes.
A review of the literature reveals multiple references to three human miRNA paralogs:
miR-103(1), miR-103(2), and miR-107. These references, along with some additional data
mining from public access databases, leads us to conclude that these paralogous miRNAs may
play a role in human metabolism. MiR-103 genes encode two identical mature miRNAs, and
a third paralogous miRNA termed miR-107 differs at a single nucleotide (both were first cloned
and sequenced by Mourelatos et al [64] from Hela cells). All three paralogs reside on different
human chromosomes (see Fig 2). miR-103 and miR-107 genes are absolutely conserved in all
known vertebrates but are not described in any invertebrate species. Some hybridization-based
profiling experiments may be nonspecific, because probes for miR-103 and miR-107 may
cross-hybridize. (Because of the near-complete sequence homology, and because there has not
been shown to be a very significant difference in the expression of these genes, we will refer
collectively to ‘miR-103/7’). Nonetheless, miR-103/7 have been shown to be expressed in
many human organs with highest concentration in brain tissue [16,55]. MiR-103/7 are
differentially expressed in a number of contexts, including during development[48,65],
oncogenesis[66], hypoxia[67], and both cold and heat stress[68,69]. The significance of
stimuli-induced changes in miR-103/107 expression has not been described. It is also of
unknown significance that, within the critical 5′ portion of miR-103/7, there is close homology
to the miRNAs miR-15 and miR-16. Both miR-15 and miR-16 are highly-expressed during
vertebrate development, and linked directly to human cancer [70].
The DNA templates for miR-103(1), miR-103(2), and miR-107 exist for all known vertebrates
within introns in the genes that encode the pantothenate kinase (PANK) enzymes. In humans,
there are at least three highly-homologous PANK genes. MiR-103(1), miR-103(2), and
miR-107 reside within PANK 3, PANK 2, and PANK1 genes, respectively. The basic
arrangement of these miRNAs in PANK genes remains constant through vertebrate evolution,
from species as varied as Tetraodon nigroviridis, Danio rerio, Fugu rubripes, Xenopus
tropicalis, Gallus gallus, Mus musculus, and Homo sapiens. The only difference is that for a
few species there is no apparent miR-103(2). The common evolutionary relative of these
species lived ~500 million years ago during the advent of invertebrates.
In order to understand the significance of the association of PANKs and miR-103/7 in the
vertebrate genome, it is important to consider the function of the polypeptide encoded by the
PANK gene. PANK enzymes serve a universal catalytic function, namely, the phosphorylation
of pantothenate (Vitamin B5)[71]. This is the rate-limiting step in generating Co-enzyme A
(CoA) and PANKs are central enzymes in the regulation of cellular CoA levels[71–75]. CoA
is a necessary cofactor in ~4% of known enzymes, including over a 100 reactions involved in
metabolism[73,76]. These enzymatic reactions include important steps in the metabolism and
synthesis of fatty acids, amino acids, cholesterol, pyruvate/lactate, glucose, and Krebs cycle
intermediates, to name a few. Interestingly, PANK2 is a gene which harbors loss-of-function
deletions in a pediatric neurodegenerative disease, termed Pantothenate kinase associated
neurodegeneration (also kown as ‘Neurodegeneration with brain iron accumulation’, formerly
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Hallervorden-Spatz syndrome)[77–79]. Neuropathologically, Pantothenate kinase associated
neurodegeneration is characterized by loss of neurons, iron pigment deposits, and axonal
swellings that are most conspicuous in the basal ganglia. It is not yet known how the expression
of miR-103 (2), which resides in PANK2 gene, is altered in that condition.
The location of miR-103/7 genes within introns of the PANK genes may be physiologically
relevant. Expression levels of intronic miRNAs and their host genes often are highly correlated,
presumably because they are co-transcribed [16,18]. In the case of miR-103, the miRNA
expression level were indirectly correlated with expression coefficients of 0.638 (PANK2) and
0.270 (PANK3)[16]. MiR-107/PANK1 levels have not been correlated. Data from microarray
experiments of mammalian tissues indicate that miR-107 and miR-103 are expressed in most
or all tissues but are evidently expressed at highest levels in the brain [16,55]. There are no
prior studies that demonstrate PANK levels in brain (but see [80]), however, we find robust
expression of all three PANK transcripts in human brain (our unpublished results).
Bioinformatics predict that miR-103/7 regulate metabolism with an emphasis on acetyl-CoA
and lipid metabolism. This is doubly interesting because PANKs regulate similar pathways.
Four different public-access databases were ‘mined’ in this study: MiRANDA (2005 build),
MiRANDA (2006 build), PicTAR, TARGETSCAN [27–29]. The latter 3 databases are
accessible through the Rfam miRNA registry, whereas the miRANDA 2005 build is accessed
through the Memorial Sloan Kettering website. These databases are each public access with
Web URLs as described in the Fig 3 legend. Each of these databases has different criteria for
predicting miRNA recognition elements in the 3′UTR of predicted mRNAs. MiRANDA 2005
and 2006 builds have rather different target predictions, because each uses different search
criteria. As shown in Fig. 3, many more mRNAs are predicted to be recognized by the miRNAs
than are shown here (for example, miRANDA predicts that over 1000 transcripts are recognized
by miR-103/107). Only genes well-known to be involved in metabolic pathways were used in
these analyses. However, it should be noted that these genes were not ‘cherry-picked’, and all
evaluated genes relevant to this discussion are shown. Figure 3 shows the results of five
additional miRNAs which, like miR-103/7, are all highly-expressed in brain. This figure shows
the total number of mRNA targets predicted by the various databases by the relevant miRNAs,
for comparison with the results of miR-103/7. Note that while miR-103/7 is predicted to target
many enzymes that are important in regulating metabolism, this is not true of most other
miRNAs, even miRNAs that are predicted to recognize more target mRNAs overall. For
example, the PDK4 mRNA transcript has a ~2.1kb long 3′UTR and all four databases predict
that miR-103/7 recognition sequence(s) are present there, however, other miRNAs shown are
not predicted to recognize sequences in this 3′UTR.
MiR-103/7 are predicted to act on genes in metabolic pathways in a manner that suggests a
coordinated function with the PANK genes (see Fig. 4). As mentioned above, the PANK genes
are known to be central players in regulating intracellular CoA[71–75]. Here we see that
miR-103/7 also acts to increase intracellular Acetyl CoA stores, and perhaps channel Acetyl
CoA into the TCA cycle. A PPAR-alpha targeted promoter has been discovered 5′upstream to
the PANK1 gene[81]. PPAR-alpha receptors are transcription factors that are stimulated by
increased (among other things) intracellular lipids/fatty acids; the function of PPAR-alpha is
thought to involve decreasing intracellular FA stores (FAs)[82–86]. These results suggest that
miR-103/7 acts symbiotically with the PANK proteins and the PPAR-alpha pathway, by
decreasing FA syntheses and uptake (by inhibiting FASN, ACOX1, and others), and increasing
the activity of the pyruvate dehydrogenase complex (by inhibiting PDK4, PISD, and PDPR).
It remains to be proven experimentally that miR-103/7 regulate multiple mRNA targets in a
pathway that involves cellular Acetyl-CoA and lipid levels. However, there are five summary
points that are strongly suggestive: 1. MiR-103/7 are present in PANK genes, which serve to
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regulate metabolism (and this relationship holds constant through vertebrate evolution); 2.
Prior studies suggest that intronic miRNAs are often expressed coordinately with their ‘parent’
protein-coding genes[15,16,18]; 3. MiR-103/7 levels are changed in states of altered cellular
metabolism, including stress[48,65,66,68,69]; 4. Most miRNAs are not predicted to target
mRNAs that encode proteins that are rate-determining enzymes in metabolic pathways (see
Fig. 3); 5. Bioinformatics predict that miR-103/7 recognizes motifs in the 3′UTR of particular
target mRNAs in metabolic pathways in a pattern that appears to complement the activity of
PANK.
Conclusion
Studies from diverse biological systems have provided evidence for miRNAs participating in
metabolic pathways. Experiments in invertebrates have determined that particular miRNAs
have important multimodal effects that include changing the metabolism of lipids. Research
in mammals has shown that miRNAs affect metabolism at many levels, including the regulation
of insulin secretion in pancreas. MiRNAs also apparently play a role in determining the cell
fate and physiology of human adipocytes. Also, miRNA-related pathways have been shown
to be an attractive candidate for pharmacological treatment of human metabolic syndromes.
With regard to ‘classical’ metabolic pathways, miR-29b participates in regulating amino acid
metabolism, and, pending experimental verification, miR-103/7 may complement PANK
genes to regulate cellular Acetyl-Coa and lipid levels.
In summary, research in miRNAs in metabolism spans many species and experimental systems.
Even in the context of a literature review, it is utterly impossible to relate all the work in a
single conceptual framework. Yet there is a common message underlying it all: this powerful
regulatory paradigm will probably provide to researchers many, many additional energizing
discoveries.
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Figure 1.
MiRNAs function by recognizing a “target mRNA” and impairing the formation of a
polypeptide from that mRNA. MiRNAs (purple) guide the Argonaute proteins (red) to a
“target” mRNA (green). After miRNAs hybridize to a sequence on the 3′UTR (untranslated
region) of the mRNA, the Argonaute protein helps to mediate translational inhibition and/or
mRNA sequestration and degradation.
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Figure 2.
A. MiR-103 and miR-107 are paralogs, which differ only at a single nucleotide near the 3′ end
of the miRNAs. B. For all known vertebrate species, each miR-103/107 paralog exists within
an intron in a gene which also encodes the pantothenate kinase enzyme, PANK. PANK genes
are shown with exons as rectangles and introns as crooked lines. Note: the exon/intron lengths
on these gene diagrams are not to scale. C. The pathway in which PANK participates is
universal, involving the phosphorylation of pantothenate as a rate-determining step in the
formation of Coenzyme A (CoA). In turn, CoA participates in many metabolic and other
biochemical reactions in all known biological species.
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Figure 3.
MiR-103/107 show an unusual tendency to target mRNAs in the lipid and pyruvate metabolic
pathways. This chart relates six different human brain-enriched miRNAs (columns) to
metabolism-related “target mRNAs” (rows) with predictions from different databases as to
which miRNAs are predicted to target which mRNAs (shaded rectangles). The top left portion
of the chart shows the four different databases that were used (see references in text). The
numbers 1–4 are also used in the chart to indicate which database(s) predicted each highlighted
miRNA/mRNA pair:
(1) MiRANDA, 2005 build via MSKCC: http://cbio.mskcc.org/cgi-bin/mirnaviewer/
mirnaviewer.pl
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(2) MiRANDA, 2006 build via Sanger: http://microrna.sanger.ac.uk/cgi-bin/targets/v4/
hit_list.pl?
(3) PicTar: http://pictar.bio.nyu.edu/
(4) TargetScan 2006 build: http://www.targetscan.org/mamm_30/
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Figure 4.
MiR-103/107 and PANKs may constitute coordinated transcription units with synergistic
cellular effects concerning cellular acetyl-CoA levels and other metabolic pathway elements.
A. A diagram shows a metabolic pathway that has been previously determined, along with
some of the metabolic nodes which are predicted to be inhibited (red) or stimulated (green;
through decrease of inhibitory targets) by miR-103/7. MiR-107 may be stimulated coordinately
with PANK1. B. Like PANKs, miR-103/7 may function to increase cellular acetyl-CoA levels,
and miR-103/7 may also inhibit the synthesis and metabolism of cellular lipids.
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